These final results, together with a former report demonstrating that a little-molecule ACKR3 agonist CCX771 reveals anxiolytic-like actions in mice,2 support the principle of focusing on ACKR3 as a novel method to modulate the opioid process, which could open new therapeutic avenues for opioid-related disorders.At that point, Microsoft Advertising